

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



(Incorporated in the Cayman Islands as an exempted company with limited liability)

(Stock code: 1873)

**COMPLETION OF FULL REDEMPTION OF
US\$280 MILLION 1.00 PER CENT GUARANTEED
CONVERTIBLE BONDS DUE 2025
(STOCK CODE: 40514)**

This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

Reference is made to the announcements (the “**Announcements**”) of Viva Biotech Holdings (the “**Company**”) dated December 18, 2020, December 30, 2020 and December 31, 2020 regarding the issuance of the US\$280 million 1.00 per cent guaranteed convertible bonds by Viva Biotech Investment Management Limited (a wholly-owned subsidiary of the Company) due 2025 (the “**Convertible Bonds**”) guaranteed by the Company and the announcements of the Company dated July 31, 2022, October 13, 2023, November 20, 2023 and November 27, 2023 regarding the partial repurchase and cancellation of the Convertible Bonds. Unless otherwise defined, capitalized terms used in this announcement have the same meanings as those defined in the Announcements.

The Company hereby announces that pursuant to the terms and conditions of the Convertible Bonds, the Bondholders holding an aggregate principal amount of US\$136,600,000 of the Convertible Bonds, representing approximately 48.8% of the aggregate principal amount of the Convertible Bonds originally issued, have exercised their option to require the Issuer to redeem all their Convertible Bonds on December 30, 2023 at 103.08% of the principal amount, together with interest accrued but unpaid to (but excluding) such date.

As of the date of this announcement, all Convertible Bonds have been redeemed and no Convertible Bonds remain outstanding. The Company has applied to The Stock Exchange of Hong Kong Limited for the withdrawal of the listing of the Convertible Bonds. Such withdrawal of listing is expected to become effective upon the close of business on January 10, 2024.

The Company considers that there will be no material impact on the financial position of the Company as a result of the aforesaid redemption of the Convertible Bonds.

By order of the Board
Viva Biotech Holdings
Mao Chen Cheney
Chairman and Chief Executive Officer

Hong Kong, January 3, 2024

As at the date of this announcement, the board of the Company comprises three Executive Directors, namely, Mr. Mao Chen Cheney (Chairman), Mr. WU Ying and Mr. Ren Delin; a Non-executive Director, namely, Mr. WU Yuting; and three Independent Non-executive Directors, namely, Mr. Fu Lei, Ms. Li Xiangrong and Mr. Wang Haiguang.

As of the date of this announcement, Mr. Mao Chen Cheney is the sole director of Viva Biotech Investment Management Limited.